• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

凝血障碍与视网膜静脉阻塞的风险。

Coagulation disorders and the risk of retinal vein occlusion.

机构信息

Department of Ophthalmology, Johann Wolfgang Goethe University Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.

出版信息

Thromb Haemost. 2010 Feb;103(2):299-305. doi: 10.1160/TH09-05-0331. Epub 2009 Nov 13.

DOI:10.1160/TH09-05-0331
PMID:20126828
Abstract

Over the past years, there has been a dramatic increase in the number of identifiable causes of thrombophilia. However, to date, there are no large, prospective studies to assess an optimal, cost-effective approach with regard to screening and case finding for thrombophilic risk factors in patients presenting with retinal vessel occlusion. Two hundred twenty-eight patients with retinal vein occlusion (RVO) and 130 age-matched healthy controls were prospectively screened for thrombophilic risk factors. Both cohorts were divided into three subgroups, depending on the patients' age at the time of the RVO or a previous thromboembolic event. Patient age < or =45 years was associated with a high prevalence of coagulation disorders (p<0.0001). Among patients < or =45 years and >45 to < or =60 years, a family history of thromboembolism was strongly associated with the presence of thrombophilic disorders. The absence of cardiovascular risk factors was found to be a strong predictor for the presence of coagulation disorders in all patient groups (< or =45 years, p=0.003; >45 to < or =60 years, p=0.0008; >60 years, p=0.001). Multivariate analysis revealed the presence of resistance to activated protein C (p=0.014), antiphospholipid antibodies (p=0.022), and deficiency of the anticoagulant proteins (p=0.05) as independent risk factors for the development of RVO among patients < or =45 years. Our results indicate that thrombophilic disorders are associated with the development of retinal vein occlusion in patients < or =45 years by the time of the RVO or a previous thromboembolic event, in patients with a family history of thromboembolism, or in patients without cardiovascular risk factors.

摘要

在过去的几年中,可识别的血栓形成倾向原因的数量急剧增加。然而,迄今为止,尚无大型前瞻性研究来评估针对视网膜血管闭塞患者的血栓形成危险因素进行筛选和病例发现的最佳、具有成本效益的方法。前瞻性筛选 228 例视网膜静脉阻塞 (RVO) 患者和 130 名年龄匹配的健康对照者的血栓形成危险因素。根据 RVO 或先前血栓栓塞事件时患者的年龄,将两个队列分为三个亚组。患者年龄≤45 岁与凝血障碍的高患病率相关(p<0.0001)。年龄≤45 岁和>45 至<60 岁的患者中,血栓栓塞史家族史与血栓形成倾向疾病的存在密切相关。在所有患者组中(年龄≤45 岁,p=0.003;>45 至<60 岁,p=0.0008;>60 岁,p=0.001),未发现心血管危险因素是凝血障碍存在的强烈预测因子。多变量分析显示,存在对活化蛋白 C 的抵抗(p=0.014)、抗磷脂抗体(p=0.022)和抗凝蛋白缺乏(p=0.05)是年龄≤45 岁患者 RVO 发展的独立危险因素。我们的结果表明,血栓形成倾向与 RVO 或先前血栓栓塞事件时≤45 岁患者的视网膜静脉阻塞的发生相关,与血栓栓塞史家族史相关,或与无心血管危险因素相关。

相似文献

1
Coagulation disorders and the risk of retinal vein occlusion.凝血障碍与视网膜静脉阻塞的风险。
Thromb Haemost. 2010 Feb;103(2):299-305. doi: 10.1160/TH09-05-0331. Epub 2009 Nov 13.
2
Factor XII deficiency: a thrombophilic risk factor for retinal vein occlusion.凝血因子 XII 缺乏症:视网膜静脉阻塞的一种血栓形成风险因素。
Am J Ophthalmol. 2004 Mar;137(3):459-64. doi: 10.1016/j.ajo.2003.10.024.
3
[Selective thrombophilia screening of young patients with retinal vein occlusion].[对年轻视网膜静脉阻塞患者进行选择性血栓形成倾向筛查]
Klin Monbl Augenheilkd. 2009 Sep;226(9):768-73. doi: 10.1055/s-0028-1109195. Epub 2009 Apr 27.
4
High prevalence of resistance to APC in young patients with retinal vein occlusion.视网膜静脉阻塞年轻患者中对阿柏西普耐药的高发生率。
Graefes Arch Clin Exp Ophthalmol. 2002 Mar;240(3):163-8. doi: 10.1007/s00417-001-0415-1. Epub 2002 Feb 22.
5
The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis.在无一般危险因素的视网膜静脉阻塞患者中,活化蛋白C(APC)抵抗和凝血因子V莱顿突变的患病率显著更高。病例对照研究和荟萃分析。
Thromb Haemost. 2008 May;99(5):925-9. doi: 10.1160/TH07-11-0658.
6
Elevated lipoprotein (a) levels are an independent risk factor for retinal vein occlusion.脂蛋白(a)水平升高是视网膜静脉阻塞的独立危险因素。
Acta Ophthalmol. 2017 Mar;95(2):140-145. doi: 10.1111/aos.13228. Epub 2016 Aug 22.
7
Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management.视网膜静脉阻塞:诊断方法、全身危险因素及治疗
Intern Med J. 2008 Dec;38(12):904-10. doi: 10.1111/j.1445-5994.2008.01720.x.
8
Familial thrombophilia and retinal vein occlusion.家族性血栓形成倾向与视网膜静脉阻塞。
Eye (Lond). 2000 Feb;14 ( Pt 1):13-7. doi: 10.1038/eye.2000.4.
9
Risk factors, antithrombotic treatment and outcome in retinal vein occlusion: an age-related prospective cohort study.视网膜静脉阻塞的危险因素、抗栓治疗和结局:一项与年龄相关的前瞻性队列研究。
Eur J Haematol. 2013 May;90(5):426-33. doi: 10.1111/ejh.12099. Epub 2013 Mar 22.
10
Activated protein C resistance is a risk factor for central retinal vein occlusion.活化蛋白C抵抗是视网膜中央静脉阻塞的一个危险因素。
Ann Ital Med Int. 2000 Jul-Sep;15(3):195-8.

引用本文的文献

1
Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Criteria on Retinal Vein Occlusion Patients.2023年美国风湿病学会/欧洲抗风湿病联盟抗磷脂综合征标准对视网膜静脉阻塞患者的影响
J Clin Med. 2025 Apr 19;14(8):2826. doi: 10.3390/jcm14082826.
2
Systemic Risk Factors in Branch Retinal Vein Occlusion: a Comprehensive Review.视网膜分支静脉阻塞的全身危险因素:综述
Maedica (Bucur). 2024 Jun;19(2):380-387. doi: 10.26574/maedica.2024.19.2.380.
3
Electrochemical Monitoring in Anticoagulation Therapy.电化学监测在抗凝治疗中的应用。
Molecules. 2024 Mar 24;29(7):1453. doi: 10.3390/molecules29071453.
4
[Cardiovascular risk factors, haemostasis and antithrombotic treatment in retinal vessel occlusion].[视网膜血管阻塞中的心血管危险因素、止血与抗栓治疗]
Ophthalmologie. 2022 Nov;119(11):1129-1139. doi: 10.1007/s00347-022-01751-y. Epub 2022 Nov 7.
5
Review: The Development of Risk Factors and Cytokines in Retinal Vein Occlusion.综述:视网膜静脉阻塞中危险因素及细胞因子的发展
Front Med (Lausanne). 2022 Jun 15;9:910600. doi: 10.3389/fmed.2022.910600. eCollection 2022.
6
Antithrombotic treatment of retinal vein occlusion: a position statement from the Italian Society on Thrombosis and Haemostasis (SISET).视网膜静脉阻塞的抗血栓治疗:意大利血栓与止血学会(SISET)的立场声明。
Blood Transfus. 2022 Jul;20(4):341-347. doi: 10.2450/2022.0276-21. Epub 2022 Jan 21.
7
Platelet and Thrombophilia-Related Risk Factors of Retinal Vein Occlusion.视网膜静脉阻塞的血小板及血栓形成倾向相关危险因素
J Clin Med. 2021 Jul 12;10(14):3080. doi: 10.3390/jcm10143080.
8
Hypercoagulability Testing and Hypercoagulable Disorders in Young Central Retinal Vein Occlusion Patients.青年型中央视网膜静脉阻塞患者的高凝状态检测和高凝状态障碍。
Ophthalmol Retina. 2022 Jan;6(1):37-42. doi: 10.1016/j.oret.2021.03.009. Epub 2021 Mar 24.
9
Technology Advancements in Blood Coagulation Measurements for Point-of-Care Diagnostic Testing.即时检验凝血测量的技术进展
Front Bioeng Biotechnol. 2019 Dec 11;7:395. doi: 10.3389/fbioe.2019.00395. eCollection 2019.
10
Altered spontaneous brain activity patterns in patients with retinal vein occlusion indicated by the amplitude of low-frequency fluctuation: A functional magnetic resonance imaging study.基于低频振幅波动的视网膜静脉阻塞患者自发脑活动模式改变:一项功能磁共振成像研究
Exp Ther Med. 2019 Sep;18(3):2063-2071. doi: 10.3892/etm.2019.7770. Epub 2019 Jul 12.